Samsung Biologics Logs $323M Contract as Biosecure Act Redirection Enters Procurement Data

0 points · first seen 12h ago · 1 outlet · 0 comments

Samsung Biologics filed a KRX disclosure naming the US Biosecure Act as sourcing rationale for a $323 million biologics manufacturing contract, marking the first time the federal law appears as a documented client rationale in Korean procurement data. The five-year deal, valued at KRW 434.3 billion, adds to Samsung Biologics' backlog now exceeding $22 billion. — Tech Times

save

· share to X · Bluesky · copy link